{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:25:14Z","timestamp":1785392714239,"version":"3.55.0"},"reference-count":190,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.kint.2018.11.008","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T05:12:23Z","timestamp":1547788343000},"page":"281-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"95","author":[{"given":"Brad H.","family":"Rovin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn J.","family":"Caster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-425X","authenticated-orcid":false,"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon G.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Chon Jun","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Glassock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Charles","family":"Jennette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Katafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Richard","family":"Kitching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mej\u00eda-Vilet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Noiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"O'Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Cheon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Au","family":"Peh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Pendergraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evang\u00e9line","family":"Pillebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney C.W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Yee-Moon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Wenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.11.008_bib1","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2018.11.008_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000167563","article-title":"The importance of sample size in the interpretation of the renal biopsy","volume":"8","author":"Corwin","year":"1988","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.11.008_bib7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/ndt\/gfu355","article-title":"Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future","volume":"29","author":"Maas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm.2261","article-title":"Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome","volume":"17","author":"Clement","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2018.11.008_bib10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(15)60050-2","article-title":"Rituximab for patients with nephrotic syndrome","volume":"385","author":"Shin","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.11.008_bib12","doi-asserted-by":"crossref","first-page":"F335","DOI":"10.1152\/ajprenal.00510.2015","article-title":"Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?","volume":"310","author":"Novelli","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2018.11.008_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrneph.2014.1","article-title":"The emergence of the glomerular parietal epithelial cell","volume":"10","author":"Shankland","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: a working proposal","volume":"43","author":"D'Agati","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D'Agati","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib16","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1016\/j.ajpath.2014.08.007","article-title":"Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease","volume":"184","author":"Smeets","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2018.11.008_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrneph.2012.286","article-title":"Genetic testing in nephrotic syndrome\u2014challenges and opportunities","volume":"9","author":"Gbadegesin","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib18","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/ndt\/gfv355","article-title":"Genetic testing in steroid-resistant nephrotic syndrome: when and how?","volume":"31","author":"Lovric","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib19","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A\u00a0single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib20","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2215\/CJN.06260614","article-title":"Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort","volume":"10","author":"Trautmann","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1681\/ASN.2012070646","article-title":"Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome","volume":"24","author":"Teeninga","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A\u00a0multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib25","first-page":"1752","article-title":"Efficacy of low-dose daily versus alternate day prednisone in children with frequently relapsing nephrotic syndrome (FRNS): open-label randomized controlled trial (RCT). Abstract FP-S25-09","volume":"31","author":"Yadav","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.11.008_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.81836","article-title":"B\u00a0cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement","volume":"2","author":"Kim","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2018.11.008_bib28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","article-title":"Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome","volume":"24","author":"Gellermann","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib29","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V124.21.2754.2754","article-title":"Screening and management of hepatitis B virus before the first rituximab infusion: We must do better!","volume":"124","author":"Masse","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2018.11.008_bib30","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1681\/ASN.2015060612","article-title":"Mayo Clinic\/Renal Pathology Society Consensus report on pathologic classification, diagnosis, and reporting of GN","volume":"27","author":"Sethi","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib31","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","article-title":"Idiopathic membranoproliferative glomerulonephritis: does it exist?","volume":"27","author":"Fervenza","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib32","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.ki.5001990","article-title":"Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies","volume":"70","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ki.2013.548","article-title":"Membranous-like glomerulopathy with masked IgG kappa deposits","volume":"86","author":"Larsen","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2015.1","article-title":"Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique","volume":"28","author":"Messias","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2018.11.008_bib35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2015.195","article-title":"Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits","volume":"88","author":"Larsen","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib36","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1681\/ASN.2014040406","article-title":"C4d as a diagnostic tool in proliferative GN","volume":"26","author":"Sethi","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1681\/ASN.2017050566","article-title":"DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN","volume":"29","author":"Andeen","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1681\/ASN.2017030306","article-title":"DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN","volume":"29","author":"Dasari","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib45","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2018.11.008_bib48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2016.10.026","article-title":"The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits","volume":"91","author":"Vignon","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2015-03-630277","article-title":"A\u00a0mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy","volume":"126","author":"Bonaud","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2018.11.008_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.kint.2016.09.004","article-title":"Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management","volume":"91","author":"Bridoux","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib52","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A\u00a0clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2018.11.008_bib55","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2018.11.008_bib56","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2018.11.008_bib57","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2018.11.008_bib58","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1038\/bcj.2017.49","article-title":"Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2018.11.008_bib59","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2018.11.008_bib60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/leu.2016.195","article-title":"Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients","volume":"31","author":"Vignon","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2018.11.008_bib61","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.kint.2018.11.008_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0000000000001930","article-title":"Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis","volume":"102","author":"Sawinski","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2018.11.008_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2018.11.008_bib64","first-page":"1164","article-title":"Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus","volume":"32","author":"Levine","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib65","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","article-title":"Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN109019","article-title":"New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy","volume":"87","author":"Ghosn","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib67","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/hep.28981","article-title":"Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy","volume":"65","author":"Artemova","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2018.11.008_bib68","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/ndt\/gfu189","article-title":"Rituximab treatment for fibrillary glomerulonephritis","volume":"29","author":"Hogan","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/j.ajkd.2013.03.031","article-title":"Long-term kidney disease outcomes in fibrillary glomerulonephritis: a case series of 27 patients","volume":"62","author":"Javaugue","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib70","doi-asserted-by":"crossref","first-page":"w13578","DOI":"10.4414\/smw.2012.13578","article-title":"Outcome of fibrillary glomerulonephritis","volume":"142","author":"Kalbermatter","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.kint.2018.11.008_bib71","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2215\/CJN.08300910","article-title":"Fibrillary glomerulonephritis: a report of 66 cases from a single institution","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib73","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib74","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.2010.13","article-title":"Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system","volume":"77","author":"Yu","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib75","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.06720615","article-title":"Clinical-morphological features and outcomes of lupus podocytopathy","volume":"11","author":"Hu","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib77","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib78","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ki.2009.136","article-title":"Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis","volume":"76","author":"Yu","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2018.11.008_bib80","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203317692419","article-title":"Prognostic significance of renal vascular pathology in lupus nephritis","volume":"26","author":"Mejia-Vilet","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1681\/ASN.2011060558","article-title":"Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes","volume":"23","author":"Haring","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib82","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/ndt\/gfm775","article-title":"The prognosis and pathogenesis of severe lupus glomerulonephritis","volume":"23","author":"Schwartz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib83","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib84","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.kint.2017.07.017","article-title":"Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits","volume":"93","author":"Rijnink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib86","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semnephrol.2015.08.002","article-title":"Genetics of lupus nephritis: clinical implications","volume":"35","author":"Munroe","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib88","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1681\/ASN.2013020148","article-title":"ABIN1 dysfunction as a genetic basis for lupus nephritis","volume":"24","author":"Caster","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2013.210","article-title":"Lupus nephritis: ancestry, genetic risk and health disparities","volume":"9","author":"Bomback","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib90","first-page":"745647","article-title":"Genetic factors in systemic lupus erythematosus: contribution to disease phenotype","author":"Ceccarelli","year":"2015","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.kint.2018.11.008_bib91","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/art.38220","article-title":"End-stage renal disease in African Americans with lupus nephritis is associated with APOL1","volume":"66","author":"Freedman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib92","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2018.11.008_bib93","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib94","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","article-title":"Histologic versus clinical remission in proliferative lupus nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib95","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.semnephrol.2015.08.008","article-title":"The kidney biopsy in lupus nephritis: past, present, and future","volume":"35","author":"Parikh","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib96","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/0961203313518625","article-title":"The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients","volume":"23","author":"Alvarado","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib97","doi-asserted-by":"crossref","first-page":"e000018","DOI":"10.1136\/lupus-2014-000018","article-title":"Role of early repeated renal biopsies in lupus nephritis","volume":"1","author":"Zickert","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2018.11.008_bib98","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib99","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib100","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/lupus-2017-000213","article-title":"Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?","volume":"4","author":"Ugolini-Lopes","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2018.11.008_bib101","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/annrheumdis-2013-203790","article-title":"Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease","volume":"73","author":"Birmingham","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib102","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/ndt\/gfs179","article-title":"Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis","volume":"27","author":"Yang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0961203314547791","article-title":"Anti-C1q antibodies in systemic lupus erythematosus","volume":"24","author":"Orbai","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib104","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.08.001","article-title":"Lupus nephritis biomarkers","volume":"185","author":"Soliman","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.kint.2018.11.008_bib105","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2018.11.008_bib106","first-page":"359647","article-title":"Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases","volume":"2012","author":"Xuejing","year":"2012","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.kint.2018.11.008_bib107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12016-010-8197-z","article-title":"Urinary biomarkers in lupus nephritis","volume":"40","author":"Reyes-Thomas","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.kint.2018.11.008_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2016.10.010","article-title":"Molecular imaging of the kidney in lupus nephritis to characterize response to treatment","volume":"182","author":"Parikh","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.kint.2018.11.008_bib109","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/lupus-2015-000112","article-title":"Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders","volume":"2","author":"Parikh","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2018.11.008_bib110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.kint.2018.11.008_bib111","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0961203313496339","article-title":"Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort","volume":"22","author":"Pons-Estel","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib112","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0961203317728810","article-title":"Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort","volume":"27","author":"Ugarte-Gil","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib113","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib114","doi-asserted-by":"crossref","first-page":"e2891","DOI":"10.1097\/MD.0000000000002891","article-title":"Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)","volume":"95","author":"Galindo-Izquierdo","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.kint.2018.11.008_bib115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/0961203316671813","article-title":"Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage","volume":"26","author":"Joo","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib116","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-017-0518-z","article-title":"Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials","volume":"37","author":"Sciascia","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.kint.2018.11.008_bib117","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A\u00a04-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.11.008_bib118","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.11.008_bib119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2018.11.008_bib120","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib121","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib122","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib123","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2215\/CJN.03640412","article-title":"Lupus nephritis: maintenance therapy for lupus nephritis: Do we now have a plan?","volume":"8","author":"Lenz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib124","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib125","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/ndt\/gfl208","article-title":"Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?","volume":"21","author":"Grootscholten","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.008_bib126","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib127","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib129","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.clinthera.2017.05.359","article-title":"Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: a systematic review and meta-analysis","volume":"39","author":"Shamliyan","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2018.11.008_bib131","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2018.11.008_bib132","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/1756-185X.12212","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"16","author":"Mok","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib133","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1097\/MD.0000000000007429","article-title":"Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study","volume":"96","author":"Chavarot","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.kint.2018.11.008_bib134","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2018.11.008_bib135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ekir.2017.04.008","article-title":"Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis","volume":"2","author":"Pattanashetti","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2018.11.008_bib136","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2018.11.008_bib137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.11.008_bib138","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.kint.2018.11.008_bib139","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s10067-017-3823-2","article-title":"Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3: a case report and systematic review","volume":"36","author":"de Holanda","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib140","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib141","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib142","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.11.008_bib143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaime","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.008_bib144","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib145","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0961203314540353","article-title":"Tacrolimus is an effective treatment for lupus nephritis in pregnancy","volume":"23","author":"Webster","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib146","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1681\/ASN.2016020126","article-title":"Kidney transplantation outcomes across GN subtypes in the United States","volume":"28","author":"O'Shaughnessy","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib147","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0961203308089439","article-title":"Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation","volume":"17","author":"Yu","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib148","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10067-011-1931-y","article-title":"Impact of recurrent lupus nephritis on lupus kidney transplantation: a 20-year single center experience","volume":"31","author":"Yu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib149","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/0961203317696591","article-title":"Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience","volume":"26","author":"Naranjo-Escobar","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2018.11.008_bib150","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1681\/ASN.2009101093","article-title":"Recurrence of lupus nephritis after kidney transplantation","volume":"21","author":"Contreras","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib151","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib152","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/acr.21558","article-title":"Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus","volume":"64","author":"Mina","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2018.11.008_bib153","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00467-014-2908-2","article-title":"Presentation and outcome of paediatric membranous non-proliferative lupus nephritis","volume":"30","author":"Hugle","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib154","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00467-017-3743-z","article-title":"Clinical presentation and outcomes of childhood-onset membranous lupus nephritis","volume":"32","author":"Pereira","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib155","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib156","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib157","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1172\/JCI65292","article-title":"Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis","volume":"123","author":"Roth","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.11.008_bib158","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib159","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib161","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib162","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1681\/ASN.2016121271","article-title":"Re-examining neutrophil participation in GN","volume":"28","author":"Caster","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib163","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.humpath.2016.01.015","article-title":"The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study","volume":"52","author":"Diaz-Crespo","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.kint.2018.11.008_bib164","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis: a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2018.11.008_bib165","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib166","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib167","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","article-title":"Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis","volume":"72","author":"Monach","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib168","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13075-017-1429-3","article-title":"Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"19","author":"Ishizaki","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.kint.2018.11.008_bib169","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2015050511","article-title":"Urinary soluble CD163 in active renal vasculitis","volume":"27","author":"O'Reilly","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib170","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib171","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib172","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib173","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib174","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib175","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib176","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib177","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib178","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2018.11.008_bib179","doi-asserted-by":"crossref","first-page":"52072","DOI":"10.18632\/oncotarget.18120","article-title":"The \"4 plus 2\" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study","volume":"8","author":"Roccatello","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.kint.2018.11.008_bib180","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A\u00a0multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib181","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.008_bib182","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib183","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.110143","article-title":"Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"39","author":"Roubaud-Baudron","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib184","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2018.11.008_bib185","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.008_bib186","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.autrev.2017.07.015","article-title":"How I treat\" autoimmune diseases: state of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis","volume":"16","author":"Roccatello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.11.008_bib187","first-page":"224","article-title":"Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey","volume":"34","author":"Wilkinson","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib188","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/art.39729","article-title":"Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an ARChiVe Cohort Study","volume":"68","author":"Cabral","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2018.11.008_bib189","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","article-title":"Biologic therapy in primary systemic vasculitis of the young","volume":"48","author":"Eleftheriou","year":"2009","journal-title":"Rheumatology"},{"issue":"suppl 103","key":"10.1016\/j.kint.2018.11.008_bib190","first-page":"202","article-title":"Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis","volume":"35","author":"James","year":"2017","journal-title":"Clin Exp Rheumatol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818308111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818308111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:51:28Z","timestamp":1758761488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818308111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":190,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0085253818308111"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.008","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}